FINALIZED SEER SINQ S NOVEMBER 2011

Similar documents
CODING TUMOUR MORPHOLOGY. Otto Visser

Methotrexate-associated Lymphoproliferative Disorders

FINALIZED SEER SINQ S MAY 2012

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014

Histology Coding ANSWERS

The European Commission s science and knowledge service. Joint Research Centre

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

SEER SINQ s. Finalized December 2010

NAACCR Webinar Series 1

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Differential Diagnosis of Oral Masses. Palatal Lesions

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

ICD-O CODING Third Edition

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

SEER SINQ S. Finalized February 2011

2010 Update. NAACCR Webinar Series 1 4/1/2010. Agenda. Access to 2010 Information. CSv2. Collecting Cancer Data: Soft Tissue Sarcoma

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

FINALIZED SEER SINQ QUESTIONS

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Stage 4 adenocarcinoma lung cancer icd 10

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.

Approach to Core Biopsy Specimens

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Using the 7 th edition American Joint Commission on Cancer (AJCC) Cancer Staging Manual to Determine Esophageal Cancer Staging in SEER-Medicare Data

Summary NAACCR: What you need to know for 2017 Version 1.1. March ICD-O-3 Histologies. Reportability There are no reportability changes in 2017.

FINALIZED SEER SINQ QUESTIONS

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO

Quiz. b. 4 High grade c. 9 Unknown

Neoplasms/Lymphoma/Leukemia

Hepatic Lymphoma Diagnosis An Algorithmic Approach

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =

Contents. vii. Preface... Acknowledgments... v xiii

Small B-cell (Histologically Low Grade) Lymphoma

Leukemia And Lymphoma In The Nervous System

FINALIZED SEER SINQ QUESTIONS

FINALIZED SEER SINQ QUESTIONS January June, 2016

FINALIZED SEER SINQ QUESTIONS April July, 2017

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor

Instructions for Coding Grade for 2014+

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

EQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH

Lymphoma: The Basics. Dr. Douglas Stewart

Corporate Medical Policy

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307

ICD-O-3 UPDATES - PENDING

ICD-O-3 UPDATES - PENDING

7/29/ Grade Coding Instructions ICD-O-3 Updates. Outline. Introduction to Coding Grade for 2014+

December 2002 Monthly Memo

NAACCR Webinar Series 1

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies

2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

I.2 CNExT This section was software specific and deleted in 2008.

DETERMINATION OF A LYMPHOID PROCESS

2018 New Grade Coding Rules It s a Good Thing!

Histopathology of NSCLC, IHC markers and ptnm classification

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA

THYMIC CARCINOMAS AN UPDATE

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

2007 Multiple Primary and

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

Colon and Rectum: 2018 Solid Tumor Rules

2018 Updates to National Standards

Immunopathology of Lymphoma

Outline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING

NAACCR Grade 2018 Q & A

IASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS

Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry

ICD-O CODING Third Edition

Mimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres

COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING

Update: Morphologic Considerations in Mesothelioma within the Pleural and Peritoneal Cavities. Douglas J. Hartman, MD June 7, 2018

Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

Boot Camp /5/15

Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012

Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification

Case 3. Ann T. Moriarty,MD

Introduction to ICD-O-3 coding rules

A Practical Guide To Diagnose B-Cell Lymphomas on FNAs. Nancy P. Caraway, M.D.

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)

Change Summary - Form 2018 (R3) 1 of 12

Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy?

2010 Cancer Data Collection Updates: Standards Volume II, Introduction. What s New for 2010

Mimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk.

Transcription:

: 20110133 Multiple primaries/heme & Lymphoid Neoplasms: A patient was diagnosed 7/31/08 with DLBCL (9680/3) (biopsy left supraclav. node), stage IIIB. Treated with chemo. 10/14/10 biopsy right supraclav. node shows follicular lymphoma grade 3A of 3 (9698/3). Does rule M12 apply since normally follicular transforms into DLBCL? Do we ignore rule M3? Do we have two primaries? See discussion. In this case, the follicular came AFTER the DLBCL. (so "acute" reverted to "chronic"?) Or do we just go on to rule M13 and use the HemaDB calculator? Use rule M12 which tells you to abstract as multiple primaries when a neoplasm is originally diagnosed in a blast phase and reverts to a chronic phase after treatment. You cannot use M3 because DLBCL and FL weren't present in the same node(s) AT THE SAME TIME. 1

: 20110132 Histology--Heme & Lymphoid Neoplasms: Is the following diagnosis reportable for a bone marrow biopsy dated 10/99/10 and what histology would be used? Bone, left posterior iliac crest, biopsy: Small B-cell Non-Hodgkin lymphoproliferative disorder. See discussion. The differential diagnosis includes atypical small lymphocytic lymphoma/chronic lymphocytic leukemia and marginal zone lymphoma. Mantle cell lymphoma is very unlikely based on BCL1 negativity. Lymphoplasmacytic lymphoma is also excluded due to absence of a plasma cell component (CD138 negative). Yes, report as non-hodgkin lymphoma, NOS 9591/3. When there is a diagnosis of lymphoproliferative disorder and any lymphoma, code the lymphoma. The information in the discussion is reflective of the difficulty in diagnosing hematopoietic and lymphoid neoplasms. The information tells you that they ruled out a number of possible specific diagnoses (which explains why the final diagnosis is non-hodgkin, NOS). 2

: 20110131 Reportability--Heme & Lymphoid Neoplasms: History of RAEB-1 in 2008. Bone marrow biopsy and a diagnosis of RAEB-2 in 2011 - same primary on the calculator (9983/3). Should this be noted anywhere besides follow-up screens? Should this case be resubmitted to our state registry? The designations of RAEB1 and RAEB2 are not showing a difference in histology. The 1 and 2 are indicative of the number of blasts that are in the bone marrow. For RAEB, the number of blasts measures the severity of the disease and also is a predictor of the chances of a genetic transformation to AML. In the case you cite, the patient's disease has progressed to a more severe phase - rather similar to a solid tumor progressing from a Stage II to a Stage III. 3

: 20110128 Histology/Primary site--heme & Lymph Neoplasms: Bone marrow biopsy shows diffuse infiltration by B-Cell lymphoma/leukemia, consisting of medium-sized cells with Burkitt morphology. Flow cytomety - No evidence of leukemia or lymphoma. What is the histology? Also, what is the primary site? Code a single primary, histology is diffuse large B-cell lymphoma 9680/3. The steps to getting this answer are: Step 1: Look up diffuse B-cell in the Hemato DB. The first matched term is DLBCL 9680/3. Step 2: Look at the alternate names. One of the alternate names is "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma." Code the primary site to bone marrow using rule PH32. 4

: 20110127 Primary Site/Brain and CNS: Are meninges surrounding cranial nerves part of C70.0 or part of the specific nerve's sheath? For example, do we code an optic nerve sheath meningioma to C72.3? Code the primary site to cranial meninges. : 20110125 MP/H Rules/Histology--Lung: What would the histology code be for a wedge bx of the left lung, lower lobe, that was read out as well differentiated adenocarcinoma with micropapillary features? Code papillary adenocarcinoma 8260/3. The ICD-O-3 codes for micropapillary have specific associations such as ductal, serous or transitional. None of those associations fit lung primaries. 5

: 20110124 MP/H Rules/Histology--Lung: What is the histology for this case? Not sure how to apply the rules with so many histologies listed. See Path report states: Lung left lower lobe lobectomy: one tumor - sarcomatoid carcinoma with features of carcinosarcoma, spindle cell carcinoma, poorly diff squamous cell carcinoma, and giant cell carcinoma. This case was sent to the lung physician experts. Their reply was as follows: This pathologist has diagnosed a sarcomatoid carcinoma, and then listed all of the subtypes associated with that diagnosis. I would go with the primary diagnosis, sarcomatoid carcinoma. The inclusion of squamous cell differentiation would exclude spindle cell and giant cell as diagnoses, so the pathologist is using them descriptively. We have no basis for picking one of the subtypes as far as I can tell, and sarcomatoid carcinoma covers all of the diagnoses given. See the glossary in the lung Equivalent Terms and Definitions: Sarcomatoid carcinoma: A group of tumors that are non-small cell in type and contain spindle cells and/or giant cells. Depending on the histologic features the tumor may be designated: pleomorphic carcinoma (8022); spindle cell carcinoma (8032); giant cell carcinoma (8031), carcinosarcoma (8980); or pulmonary blastoma (8972). History : 20110123 Add to Report Reportability--Heme & Lymphoid Neoplasms: We have several questions about EBV positive B-cell lymphoproliferative disorder and reportability related to variants of this diagnosis. See. 6

1) Does the diagnosis of EBV positive B-cell lymphoproliferative disorder specifically have to include "of the elderly" to be reportable or is there a certain age criteria that is equivalent to "of the elderly". 2) Is "iatrogenic EBV positive lymphoproliferative disorder" reportable? 3) Is just EBV positive B-cell lymphoproliferative disorder reportable (when there is no further classification of the LPD as lymphoma)? The diagnosis "iatrogenic" simply means that there is no known cause for the disease. Code as EBV positive lymphoproliferative disorder 9680/3, the term "of the elderly" does not have to be part of the diagnosis. EBV positive B-cell lymphoproliferative disorder is a synonym for DLBCL 9680/3. You do not need to have the lymphoma (DLBCL) diagnosis. : 20110122 Histology--Heme & Lymphoid Neoplasms: Please advise as to the histology code. I was using 9861/3, but was unsure if trisomy 13 changed the histology as when I type trisomy 13 in the Heme DB 9871/3 and 9911/3 are options. Are these codes related to trisomy 13? See discussion. We have a path report of a bone marrow biopsy stating that the diagnosis is AML evolving from MDS. The patient had no previous diagnosis of MDS. Cytogenetics revealed trisomy 13 with no other genetic abnormalities. Code to AML 9861/3 using rule M7. You do not have enough information to code a specific AML. The reason you are getting both 9871/3 and 9911/3 is because you entered trisomy 13. The DB tries to match both of the words you entered, meaning it will give you results for all diseases with the word trisomy and will also give you all results for diseases with the number 13. Both 9871/3 and 9911/3 have genetic abnormalities with p13 and 9911/3 also has abnormalities in q13. So you got matches for the number 13. If you want only trisomy 13, use quotation marks "trisomy 13" when you type the search phrase and you will only get results for that exact wording. 7

: 20110121 MP/H Rules/Histology--Esophagus: Is coding the histology for esophageal cancers going to change to reflect the following? See discussion. CS Esophageal Schema Note 4: Effective with AJCC TNM 7th Edition, there are separate stage groupings for squamous cell carcinoma and adenocarcinoma. Since squamous cell carcinoma typically has a poorer prognosis than adenocarcinoma, a tumor of mixed histopathologic type or a type that is not otherwise specified should be classified as squamous cell carcinoma? Code the histology to adenosquamous carcinoma. Do NOT use the CS manual to determine the histology code. The MPH Manual is the correct source for coding histology. In this case, CS is saying that the STAGING should be based on the squamous cell carcinoma.component of this tumor. History 8